LogoCrystal's MCW Coder Hub

E11.3592

7 min read

🧬ICD-10 CM E11.3592 - Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

Overview

ICD-10 CM E11.3592 is a specific combination code used to classify Type 2 diabetes mellitus complicated by proliferative diabetic retinopathy (PDR) without macular edema, specifically localized to the left eye. This code captures the systemic disease, the specific ocular complication, the severity of the retinopathy (proliferative), the absence of edema, and the laterality in a single alphanumeric string.

Accurate coding of E11.3592 is critical for risk adjustment, severity of illness scoring, and ensuring appropriate reimbursement. It distinguishes the condition from nonproliferative diabetic retinopathy (NPDR) codes (such as E11.3392 or E11.3492), indicating a more advanced stage of disease with neovascularization, which carries higher clinical risk and resource utilization. It also differentiates cases without macular edema from those with edema (E11.3512).

Code Breakdown

The structure of E11.3592 follows the ICD-10-CM taxonomy:

SegmentValueDescription
CategoryE11Type 2 diabetes mellitus
SubcategoryE11.3Type 2 diabetes mellitus with ophthalmic complications
ExtensionE11.35Type 2 diabetes mellitus with proliferative diabetic retinopathy
Further ExtensionE11.359Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
Laterality2Left eye

Laterality Specifics

  • 1: Right eye
  • 2: Left eye
  • 3: Bilateral
  • 9: Unspecified eye

Laterality Requirement

When documenting diabetic retinopathy, the specific eye affected must be documented. If bilateral, use E11.3593. If unspecified, use E11.3599, though unspecified codes should be avoided when clinical documentation supports specificity.

Coding Guidelines

Includes

  • Type 2 diabetes mellitus with proliferative diabetic retinopathy (PDR).
  • Absence of macular edema associated with the retinopathy.
  • Diabetes mellitus NOS (if documented as Type 2).
  • Adult-onset diabetes (if documented as Type 2).
  • Ketosis-resistant diabetes (if documented as Type 2).
  • Neovascularization of the iris (NVI) or retina associated with diabetes.
  • Vitreous hemorrhage associated with proliferative diabetic retinopathy (unless specified as the primary reason for encounter requiring separate coding).

Excludes

  • Type 1 Diabetes: If the patient has Type 1 diabetes, codes from category E10 must be used (e.g., E10.3592).
  • Drug/Chemical Induced: If diabetes is caused by drugs or chemicals, use category E09.
  • Other Specified Diabetes: Use category E13 for other specified types.
  • Nonproliferative Retinopathy: If the retinopathy is nonproliferative (mild, moderate, or severe), codes from the .31, .33, or .34 series are required (e.g., E11.3492).
  • Macular Edema: If macular edema is present, codes from the .351 series are required (e.g., E11.3512).
  • Background Retinopathy: Use specific PDR codes instead of background terminology.

Use of Additional Codes

While E11.3592 is a combination code, additional codes may be required to fully capture the clinical picture:

  • Long-term insulin use: Z79.4 (if the patient uses insulin, even though it is Type 2).
  • Long-term use of oral hypoglycemic drugs: Z79.84.
  • Insulin pump status: Z99.1 (if applicable).
  • Body Mass Index (BMI): Z68.- (if documented).
  • Visual Impairment: If the patient has blindness or low vision due to the condition, add codes from H54.-.
  • Glaucoma: If diabetic glaucoma is present, code separately (e.g., H40.-).
  • Traction Retinal Detachment: If present, code separately (e.g., H33.4).

Risk Adjustment (HCC)

Hierarchical Condition Category (HCC) status is critical for Medicare Advantage and ACA plans.

  • HCC Status: Yes CMS-HCC V28
  • HCC ID: 18 (Diabetes with Chronic Complications)
  • RAF Impact: This code contributes to the Risk Adjustment Factor (RAF) score. Diabetes with chronic complications (like proliferative retinopathy) carries a higher risk weight than uncomplicated diabetes.
  • Recapture: This condition must be documented and coded at least once per calendar year to maintain the HCC status for risk adjustment purposes.
  • Severity: Proliferative retinopathy indicates the highest level of diabetic eye disease severity short of blindness, significantly impacting care management stratification.

Inpatient Impact (MS-DRG)

In the inpatient setting, E11.3592 influences the Medicare Severity Diagnosis Related Group (MS-DRG) assignment through Complication/Comorbidity (CC) logic.

  • CC/MCC Status: CC (Complication/Comorbidity) CMS MS-DRG v42
  • Impact: The presence of this code may shift a DRG from a “without CC/MCC” tier to a “with CC” tier, increasing the relative weight and reimbursement for the stay.
  • POA Indicator: Present on Admission (POA) reporting is required for inpatient claims. If the retinopathy was present before admission, mark Y.

Code Tree

Chapter 4: Endocrine, Nutritional and Metabolic Diseases (E00-E89)
└── Diabetes mellitus (E08-E13)
    └── Type 2 diabetes mellitus (E11)
        └── Type 2 diabetes mellitus with ophthalmic complications (E11.3)
            └── Type 2 diabetes mellitus with proliferative diabetic retinopathy (E11.35)
                └── Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema (E11.359)
                    └── E11.3591 (Right eye)
                    └── E11.3592 (Left eye)
                    └── E11.3593 (Bilateral)
                    └── E11.3599 (Unspecified eye)

Clinical Coding Examples

Example 1: Routine Retina Follow-up

Scenario: A patient with known Type 2 diabetes presents for a routine retina follow-up. Dilated exam reveals proliferative diabetic retinopathy without macular edema in the left eye. Right eye shows severe NPDR without edema. Coding:

  • Primary: E11.3592 (PDR without ME, Left Eye)
  • Secondary: E11.3491 (Severe NPDR without ME, Right Eye)
  • Note: Code the most severe manifestation as the primary diabetes code if applicable, or sequence based on reason for visit.

Example 2: Bilateral Involvement

Scenario: Patient has Type 2 diabetes. Exam shows proliferative diabetic retinopathy without macular edema in both eyes. Coding:

Example 3: Development of Macular Edema

Scenario: Patient previously coded with E11.3592 returns. Exam now shows proliferative diabetic retinopathy with macular edema in the left eye. Coding:

  • Primary: E11.3512 (Type 2 diabetes with proliferative diabetic retinopathy with macular edema, left eye).
  • Note: The code changes to reflect the development of edema.

Example 4: Insulin Usage

Scenario: Patient with Type 2 diabetes coded as E11.3592 is on long-term insulin therapy. Coding:

  • Primary: E11.3592
  • Secondary: Z79.4 (Long term (current) use of insulin)

Revenue Cycle Considerations

  • wRVU: Not Applicable. ICD-10-CM codes do not have work Relative Value Units. wRVUs are assigned to CPT/HCPCS procedure codes.
  • Assistant Payable: Not Applicable. This attribute applies to surgical CPT codes.
  • Denial Risk: High if paired with incompatible procedure codes (e.g., anti-VEGF injection without documented macular edema, as E11.3592 specifies without macular edema).
  • Query Opportunity: If documentation states “Diabetic Retinopathy” without specifying “Nonproliferative” vs “Proliferative,” a clinical documentation improvement (CDI) query is recommended. Proliferative status changes the HCC risk profile and treatment plan (e.g., panretinal photocoagulation vs. focal laser).
  • E11.3591: Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
  • E11.3593: Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
  • E11.3512: Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
  • E11.3492: Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
  • E10.3592: Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
  • Z79.4: Long term (current) use of insulin

Clinical Criteria for Proliferative Diabetic Retinopathy (PDR)

Proliferative Diabetic Retinopathy is characterized by the growth of new blood vessels (neovascularization) on the retina or optic disc. Key features include AAO Preferred Practice Pattern:

  • Neovascularization: New vessel growth on the disc (NVD) or elsewhere (NVE).
  • Vitreous Hemorrhage: Bleeding into the vitreous cavity from fragile new vessels.
  • Fibrous Proliferation: Scar tissue formation associated with new vessels.
  • Traction Retinal Detachment: Scar tissue pulling the retina away from the back of the eye.
  • Neovascularization of the Iris (NVI): Also known as rubeosis iridis.
  • Absence of Macular Edema: For E11.3592, clinical imaging (OCT) must confirm no thickening or fluid accumulation in the macula.

Treatment Implications

PDR typically requires panretinal photocoagulation (PRP) laser therapy and/or intravitreal anti-VEGF injections. Documentation of these treatments supports the severity of the diagnosis coded as E11.3592. However, anti-VEGF is often specifically indicated for PDR with macular edema; coding E11.3592 (without edema) alongside anti-VEGF claims may trigger medical necessity reviews unless PDR-specific indications are documented.

CMS ICD-10-CM Official Guidelines for Coding and Reporting FY 2025 CMS-HCC Risk Adjustment Model V28 Summary CMS MS-DRG Definitions Manual v42 NCHS ICD-10-CM Tabular List 2025 American Academy of Ophthalmology Preferred Practice Pattern

Graph View

Recent Notes